Please assess the completion status of the following clinical trial:

Trial Title: Ga-68-DOTATOC -PET in the Management of Pituitary Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Naïve, unoperated pituitary tumour with GH or ACTH or TSH production or NFPA without treatment with somatostatin analogues or dopamine agonists.~Exclusion Criteria:~* Patient who may not attend to the protocol according to the investigators opinion.~* Pregnancy or lactating~* Isolated prolactin producing tumours~* Overproduction of gonadotrophins~* Carcinoids ie ectopic CRF production~* Known or suspected allergy to the trial product or related products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68 DOTATOC PET in pituitary adenomas (Type: EXPERIMENTAL): To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).